The suit by GenBioPro, the generic maker of mifepristone, is the latest strand in the intense legal battle over abortion pills.
Category: Drugs (Pharmaceuticals)
-
Insurers Are Starting to Cover Telehealth Abortion
Several insurers will cover abortions through Hey Jane, a start-up online provider, just as courts threaten to hobble the industry.
-
Virtual Clinics Have Been a Fast-Growing Method of Abortion. That Could Change.
So far, most telemedicine providers seem undaunted by court rulings that could imperil their business.
-
Appeals Court Says Abortion Pill Can Remain Available but Imposes Temporary Restrictions
The judges blocked the drug from being sent to patients through the mail and rolled back other steps the government had taken to ease access.
-
Pfizer CEO and Other Drug Company Leaders Condemn Texas Abortion Pill Ruling
More than 250 executives said that the decision ignored both scientific and legal precedent and, if it stands, would create uncertainty for the pharmaceutical and biotech industries.
-
Abortion Ruling Could Undermine the F.D.A.’s Drug-Approval Authority
Legal scholars say the ruling by a Texas judge, if upheld, could spur disputes over many medications and upend the drug industry’s reliance on the agency.
-
Johnson & Johnson Reaches $8.9 Billion Talc Settlement
The company faces a flood of lawsuits claiming its talc products caused cancer. The proposed settlement requires approval by a bankruptcy court, but has the backing of plaintiffs’ lawyers.
-
F.D.A. Approves Narcan for Over-the-Counter Sales
The nasal spray reverses opioid overdoses and public health officials hope that making it more widely available could save lives and reduce the nation’s high rates of drug fatalities.
-
Over-the-Counter Narcan Could Save More Lives. But Price and Stigma Are Obstacles
The Food and Drug Administration is expected this week to allow the overdose-reversal medication to be sold without a prescription, a step toward making it a common emergency tool.
-
California’s Plan for Cheaper Insulin Collides With Big Pharma’s Price Cuts
The state awarded a $50 million contract to produce less costly treatments, but moves by major suppliers might undercut the initiative before any new product emerges.
-
Rising Rate of Drug Shortages Is Framed as a National Security Threat
A Senate homeland security committee examined growing health care shortages amid reports of rationing within hospitals.
-
Sanofi Plans to Cut the Price of Insulin
The company is the third of the three major insulin manufacturers that dominate the U.S. market to announce such a move this month.